MA39908A - Composition médicinale comprenant un composé pyrazine carboxamide utilisé comme principe actif - Google Patents
Composition médicinale comprenant un composé pyrazine carboxamide utilisé comme principe actifInfo
- Publication number
- MA39908A MA39908A MA039908A MA39908A MA39908A MA 39908 A MA39908 A MA 39908A MA 039908 A MA039908 A MA 039908A MA 39908 A MA39908 A MA 39908A MA 39908 A MA39908 A MA 39908A
- Authority
- MA
- Morocco
- Prior art keywords
- inhibiting effect
- cancers
- jak3
- itk
- btk
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000004480 active ingredient Substances 0.000 title abstract 2
- 229960005206 pyrazinamide Drugs 0.000 title 1
- -1 pyrazine carboxamide compound Chemical class 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 6
- 230000002401 inhibitory effect Effects 0.000 abstract 6
- 108091000080 Phosphotransferase Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000020233 phosphotransferase Human genes 0.000 abstract 2
- 108091008875 B cell receptors Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical class NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Le problème décrit par la présente invention est de fournir une composition médicinale destinée à traiter un cancer dans lequel participe au moins une kinase choisie parmi la btk, la jak3 et l'itk. Suite aux résultats d'études sur des composés ayant un effet inhibiteur sur la btk, un effet inhibiteur sur la jak3 et un effet inhibiteur sur l'itk, les présents inventeurs ont confirmé que des composés pyrazine carboxamide spécifiques présentent un effet inhibiteur sur la btk, un effet inhibiteur sur la jak3 et un effet inhibiteur sur l'itk, et que des compositions médicinales comprenant ces composés utilisés comme principe actif présentent un effet thérapeutique sur des cancers dans lesquels participe au moins une kinase choisie parmi la btk, la jak3 et l'itk, des cancers dans lesquels la btk est surexprimée ou activée dans un autre mode de réalisation, des cancers dans lesquels sont activés des signaux de récepteurs de lymphocytes b dans encore un autre mode de réalisation, des cancers dans lesquels la jak3 a subi une mutation-activation dans encore un autre mode de réalisation, et des cancers dans lesquels l'itk est activée dans encore un autre mode de réalisation, achevant ainsi la présente invention.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014109952 | 2014-05-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA39908A true MA39908A (fr) | 2015-12-03 |
Family
ID=54698952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA039908A MA39908A (fr) | 2014-05-28 | 2015-05-27 | Composition médicinale comprenant un composé pyrazine carboxamide utilisé comme principe actif |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20170196859A1 (fr) |
| EP (1) | EP3150206A1 (fr) |
| JP (1) | JPWO2015182628A1 (fr) |
| KR (1) | KR20170005820A (fr) |
| CN (1) | CN106456636A (fr) |
| AU (1) | AU2015266552A1 (fr) |
| CA (1) | CA2949028A1 (fr) |
| EA (1) | EA201692479A1 (fr) |
| IL (1) | IL249010A0 (fr) |
| MA (1) | MA39908A (fr) |
| MX (1) | MX2016015551A (fr) |
| PH (1) | PH12016502313A1 (fr) |
| SG (1) | SG11201609837WA (fr) |
| TW (1) | TW201625254A (fr) |
| WO (1) | WO2015182628A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2017013788A (es) | 2015-04-27 | 2018-03-27 | Astellas Pharma Inc | Composicion farmaceutica estabilizada. |
| JP2019014653A (ja) * | 2015-11-27 | 2019-01-31 | アステラス製薬株式会社 | がん免疫を介したがん治療方法 |
| WO2018079570A1 (fr) | 2016-10-26 | 2018-05-03 | アステラス製薬株式会社 | Composition pharmaceutique stable |
| MX2024008057A (es) | 2021-12-30 | 2024-08-28 | Biomea Fusion Inc | Compuestos de pirazina como inhibidores de flt3. |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ603525A (en) * | 2008-06-27 | 2015-02-27 | Celgene Avilomics Res Inc | Pyrimidine based compound and uses thereof |
| MX342164B (es) * | 2010-06-23 | 2016-09-19 | Hanmi Science Co Ltd | Derivados de pirimidina fusionados novedosos para la inhibicion de la actividad de tirosina cinasa. |
| EA026353B1 (ru) * | 2012-01-17 | 2017-03-31 | Астеллас Фарма Инк. | Соединение пиразинкарбоксамида |
-
2015
- 2015-05-27 MA MA039908A patent/MA39908A/fr unknown
- 2015-05-27 EA EA201692479A patent/EA201692479A1/ru unknown
- 2015-05-27 US US15/314,364 patent/US20170196859A1/en not_active Abandoned
- 2015-05-27 KR KR1020167033075A patent/KR20170005820A/ko not_active Withdrawn
- 2015-05-27 CA CA2949028A patent/CA2949028A1/fr not_active Abandoned
- 2015-05-27 EP EP15799603.4A patent/EP3150206A1/fr not_active Withdrawn
- 2015-05-27 MX MX2016015551A patent/MX2016015551A/es unknown
- 2015-05-27 SG SG11201609837WA patent/SG11201609837WA/en unknown
- 2015-05-27 JP JP2016523519A patent/JPWO2015182628A1/ja active Pending
- 2015-05-27 AU AU2015266552A patent/AU2015266552A1/en not_active Abandoned
- 2015-05-27 CN CN201580026409.3A patent/CN106456636A/zh active Pending
- 2015-05-27 TW TW104116974A patent/TW201625254A/zh unknown
- 2015-05-27 WO PCT/JP2015/065154 patent/WO2015182628A1/fr not_active Ceased
-
2016
- 2016-11-16 IL IL249010A patent/IL249010A0/en unknown
- 2016-11-21 PH PH12016502313A patent/PH12016502313A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2016015551A (es) | 2017-03-23 |
| EP3150206A1 (fr) | 2017-04-05 |
| PH12016502313A1 (en) | 2017-02-13 |
| KR20170005820A (ko) | 2017-01-16 |
| JPWO2015182628A1 (ja) | 2017-04-20 |
| WO2015182628A1 (fr) | 2015-12-03 |
| TW201625254A (zh) | 2016-07-16 |
| CA2949028A1 (fr) | 2015-12-03 |
| AU2015266552A1 (en) | 2016-12-01 |
| EA201692479A1 (ru) | 2017-03-31 |
| CN106456636A (zh) | 2017-02-22 |
| IL249010A0 (en) | 2017-01-31 |
| SG11201609837WA (en) | 2016-12-29 |
| US20170196859A1 (en) | 2017-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020550901A1 (en) | Macrocyclic compounds for treating disease | |
| EA033343B1 (ru) | Соединения, ингибирующие rip2-киназу, фармацевтическая композиция на их основе и их применение для лечения заболеваний, опосредуемых rip2-киназой | |
| MX2019001125A (es) | Inhibidores de cinasa macrociclica. | |
| PH12016501578B1 (en) | Pharmaceutical compounds | |
| MY199705A (en) | Heterocyclic compounds as immunomodulators | |
| PH12018500899B1 (en) | Compositions and methods for inhibiting arginase activity | |
| PH12018501084A1 (en) | Heterocyclic compounds as immunomodulators | |
| PH12016501963A1 (en) | Macrocyclic pyrimidine derivatives | |
| PH12016501962A1 (en) | Macrocyclic pyridine derivatives | |
| MX2022001310A (es) | Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo. | |
| MX2018000419A (es) | Derivados de amida sustituida que tienen actividad multimodal contra el dolor. | |
| PH12016501527B1 (en) | Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient | |
| PT3279210T (pt) | Péptido com atividade anticancerígena, composição farmacêutica e composição de suplementos alimentares para prevenção e tratamento do cancro, ambos os quais contêm o mesmo ingrediente ativo | |
| PH12016502313A1 (en) | Pharmaceutical composition comprising pyrazine carboxamide compound as active ingredient | |
| MX2018007517A (es) | Compuestos triciclicos y composiciones como inhibidores de quinasa. | |
| MX2018004774A (es) | Derivados de morfolina sustituidos que tienen actividad contra el dolor. | |
| PH12017501334A1 (en) | 3,5-diaminopyrazole kinase inhibitors | |
| MX2017007648A (es) | Composicion farmaceutica que comprende compuesto biciclico de amida heterociclica aromatica que contiene nitrogeno como ingrediente activo. |